Bibliography of studies with dendritic cell therapy. Updated June 22, 2011
June 22, 2011: Please read the recently added information about Dr. Robert Gorter and Medical Center in Cologne this information: My experience with dr.Robert Gorter and the Medical Center Cologne. A warning
And click here for addresses of clinics in Germany, where dendritic cell therapy is given .
Experiences of cancer patients with dendritic cell therapy can be on video if you click here or on the video button top left of this page. An educational video on dendritic cell can bekjken on the website of the SNFK video below.
Bibliography of studies with dendritic cell therapy dated 2005. See further on this page for more recent studies:
1. Steinmann RM: The dendritic cell system and its role in immunogenicity.Ann Rev. Immunol. (1991) 9:271-296
2. Fan Z, Huan XL, Borowski L, Mellors JW, Rinaldo CR: Restoration and anti-human immunodeficiency virus type 1 (HIV-1) responses in CD8 + T cells from late-stage Patients on prolonged antiretroviral therapy by stimulation in vitro with HIV a protein-loaded dendritic cells. J Virol (2001) May, 75 (9): 4413-4419
3. Caux C et al: GM-CSF and TNF-alpha coop rate in the generation of dendritic Langerhans cells. Nature (1992) 360: 258-261
4. Santiago-Schwarz F et al: TNF in combination with GM-CSF Enhances the differentiation of neonatal cord blood stem cells enter cell and dendritic macrophages.J Leukoc Biol (1992) 52: 274-281
5. Herbst B et al: In vitro differentiation of CD34 + hematopoietic progenitor cells distinct dendritic cell subsets Toward Birbeck granule and MIIC-of-the-positive Langerhans cells and interdigitating dendritic cell type.Blood the (1996) 88: 2541-2548
6. Sallusto F, Lanza Vecchia A: Efficient presentation of soluble antigen by cultured human dendritic cells is Maintained by granulocyte / macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.J Exp Med. (1994) 179: 1109-1118
7. Peters J et al: Dendritic cells: From lack genetic orphans to myelo-monocytic descendants. Immunol Today (1996) 17:273-278
8. Mayordomo J et al: Bone Marrow Derived Dendritic Cells Serve as-Potent Adjuvant for Peptide-Based Antitumor Vaccines.Stem cells (1997) 15: 94-103
9. Hsu FJ et al: Vaccination of Patients with B-cell lymphoma Using autologous dendritic cells pulsed antigen. Nat Med (1996) 2: 52-58
10. Dietz AB, Litzow MR, Gastineau DA, Vuk-Pavlovic S: Engineering dendritic cell grafts for clinical trials in cellular immunotherapy of cancer: chronic myelogenous leukemia or example. Croat Med J (2001) 42 (4): 427-434
11. Sangro B, Qian C, Schmitz V, Prieto J: Gene therapy of hepatocellular carcinoma and gastrointestinal tumors. Ann NY Acad Sci (2002), 963: 6-12.
12. Qiu S, Ye S, Tang Z, Qian S, Li L: Feasibility of Using hepatitis B surface antigen as target antigen in immunogeng therapy against cancer. Zhonghua Yi Xue Za Zhi (2002) 82: 253-256.
13. Liu B, Ye S, He P, Zheng N, Zhao, Sun R, Tang Z: Study of the cytotoxicity against human hepatocellular carcinoma cells induced by the MAGE-1 gene modified dendritic cells. Zhonghua Gan Zang Bing Za Zhi (2001) 9: 151-153.
14. Liu B, Ye S, He P, Xue Q, Gao D, Tang Z: Antitumor activities in vivo or interleukin-12 gene modified dendritic cells in murine models. Zhonghua Gan Zang Bing Za Zhi (2000) 8: 350-351.
15. Pedersen IM, Kitada S, Leoni LM, Zapata JM, Karras JG, Tsukada N, Kipps TJ, Choi YS, bennetti F, Reed JC: Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1. Blood (2002) September 1, 100 (5) :1795-1801.
16. Ruffini PA, Kwak LW: Immunotherapy of multiple myeloma. Semin Hematol (2001) 38:260-267.
17. Gong J, Koido S, Chen A, Tanaka Y, Huang L, Avigan D, Anderson K, Ohno T, Kufe D: Immunization against murine multiple myeloma with infusions of dendritic cells and plasmacytoma is potentiated by interleukin-12. Blood (2002) 99:2512-2517.
18. Liu Y, Zhang W, Chan T, Saxena A, Xiang J: Engineered fusion hybrid vaccine of IL-4 gene-modified myeloma and relative mature dendritic cells Enhances antitumor immunity. Lek Res (2002) 26:757-763.
19. Zeis M, Frenzke H, Schmitz N, Uharek L, Steinmann J: idiotype protein-pulsed dendritic cells produce strong ant-myeloma effects after syngeneic stem cell transplantation in mice. Bone Mattow Transplant (2002) 29:213-221.
20. Cull GM, Timms JM, Haynes AP, Russell NH, Irving WL, Ball JK: Dendritic cells cultured from mononuclear cells and CD34 cells in myeloma do not harbor human herpes virus 8. Br J Haematol (1998) 100:793-796.
21. Valone FH, Small E, MacKenzie M, Burch P, Lacy M, Peshwa MV, Laus R: Dendritic cell-based treatment of cancer: closing in on a cellular therapy. (In print).
22. Tanaka F, Yamaguchi H, Ohta M, Mashino K, Sonoda H, Sadanaga N, Inoue H, Mori M: Intratumoral injection of dendritic cells after treatment or anti-cancer drugs induces tumor-specific antitumor effect in vivo. Int J Cancer (2002) September 20, 101 (3) :265-269.
23. Stift A, Friedl J, Dubsky P, Bach Leitner T Hofmann, T Benkoe, Brostjan C Jakesz R, Gnant M: In vivo induction of dendritic cell-mediated cytotoxicity against allogeneic pancreatic carcinoma cells. Int J Oncol. March 2003, 22 (3) :651-6.
24. Engleman EG: Dendritic cell-based cancer immunotherapy. Semin Oncol (2003) 30 (Suppl 8) :23-29.
25. Freudenthal PS Engleman EC: The distinctsurface of human blood dendritic cells, as observed after an improved isolation method. Proc Natl Acad Sci USA 87: 7698-7702, 1990.
26. Markowicz S, Englenman EG: Granulocyte-macrophage colony-stimulating factor promotes differentiation and survival of human peripheral blood dendritic cells in vitro. J Clin Invest 85: 9555-961, 1990.
27. Mehta-Damani A., Markowicz S, Englenman EC: Generation of antigen-specific CD8 + CTLs from naive precursors. J Immunol 153:996-1003, 1994.
28. Mehta-Damani A., Markowicz S, Englenman EC: Generation of antigen-specific CD4 + T cell lines from naive precursors. J Immunol 25: 1206-1211, 1995.
29. Hsu FJ, C BENIKE, Fagnon F, et al: Vaccination of Patients with B cell lymphoma antigen-pulsed dendritic Using autolugus cells. Nature Med 2:52-58, 1996.
30. Timmerman JM, Czerwinski DK, Davis TA, et al: idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: Clinical and immune responses in 35 patients. Blood 99:1517-1526, 2002.
31. Liso A, Stocherl-Goldstein KE, Auffermann-Gretzinger S, et al: Using idiotype vaccination dendritic cells after peripheral blood progenitor cell autolugus trasplnatation for multiple myeloma. Biol Blood Marrow Transplant 6:621-627, 2000.
32. Fecci PE, Mitchell DA, Archer GE, Morse MA, Lyerly HK, et al: The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors. Journal of Neuro-Oncology 64: 161-176, 2003.
33. F Patrone, M Valbonesi, Alberto Ballestrero: Autologous peripheral blood stem cells (PBSC) in breast cancer. Transfunsion and apheresis science 27 (2002) 167-173.
34. Office for National Statistics, Morality, statistics, cause No. 21, series DH2, HMSO, 1996.
35. Wojas K, Tabarkiewicz J, Jankiewicz M, Rolinski J: Dendritic cells in peripheral blood or patient with breast and lung cancer a pilot study. Folia Histochem Cytobiol. 2004, 42 (1): 45-8.
36. Pockaj BA, Basu GD, Pathangey LB, Gray RJ, Hernandez JL, Gendler SJ, Mukherjee P. Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 expression and prostaglandin E2 on secretion in patients with breast cancer. Ann Surg Oncol. 2004 March; 11 (3) :328-39.
37. Manna PP, Jaramillo A, Majumder K, Campbell LG, Fleming TP, Dietz JR, Dipersio JF, Mohanakumar T: Generation of CD8 + cytotoxic T lymphocytes against breast cancer cells by stimulation with mammaglobin-A-pulsed dendritic cells. Breast Cancer Res Treat. 2003 May; 79 (1) :133-6.
38. Para Doll DM. Topalian SL: The role of CD4 + T cell responses in antitumor immunity. Curr Opin Immunol 10: 588-594, 1998.
39. Bigotti G, Coli A, Castagnola D: Distribution of Langerhans cells and HLA class II molecules in prostatic carcinomas of different histopathological grade. Prostate. 1991, 19 (1) :73-87.
40. Tjoa B, Boynton A, Kenny G, Ragde H, Misrock SL, Murphy G. Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity. Prostate. January 1996, 28 (1) :65-9.
41. Murphy G, Tjoa B, Ragde H, Kenny G, Boynton A. Phase I clinical trial: T-cell therapy for prostate cancer Using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate. December 1996, 29 (6) :371-80.
42. Tjoa BA, Erickson SJ, Bowes VA, Ragde H, Kenny GM, Cobb OE, Ireton RC, Troychak MJ, Boynton AL, Murphy GP: Follow-up evaluation of prostate cancer with autologous dendritic cells infused Patients pulsed with PSMA peptides. Prostate. 1997 September 1, 32 (4) :272-8.
43. Slovin SF, Kelly WK, Scher HI: Immunological approaches for the treatment of prostate cancer. Semin Urol Oncol. February 1998, 16 (1) :53-9. Review
44. Salgaller ML, Lodge PA, McLean JG, Tjoa BA, Loftus DJ, Ragde H, Kenny GM, Rogers M, Boynton AL, Murphy GP.: Report of immune monitoring of prostate cancer Patients under-going T-Cell Therapy Using Dendritic cells pulsed with HLA -A2-Specific peptides from prostate-specific membrane antigen (PSMA). The Prostate 35:144-151 (1998).
45. Salgaller ML, Tjoa BA, Lodge PA, Ragde H, Kenny G, Boynton A, Murphy GP.Dendritic cell based immunotherapy of prostate cancer. Crit Rev Immunol. 1998, 18 (1-2) :109-19.
46. Tjoa BA, Simmons SJ, Bowes VA, Ragde H, Rogers M, ElGamal A, Kenny GM, Cobb OE, Ireton RC, MJ Troychak, Salgaller ML, Boynton AL, Murphy GP: Evaluation of phase I / II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate. 1998 June 15, 36 (1) :39-44.
47. Peshwa MV, Shi JD, Ruegg C, Laus R, van Schooten WC.Induction or prostate tumor-specific CD8 + cytotoxic T lymphocytes in vitro antigen-presenting cells Using pulsed with prostatic acid phosphatase peptide. Prostate. 1998 July 1, 36 (2) :129-38.
48. Simmons SJ, Tjoa BA, Rogers M, ElGamal A, Kenny GM, Ragde H, Troychak MJ, Boynton AL, Murphy GP: GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial. Prostate. 1999 Jun 1; 39 (4) :291-7.
50. Murphy GP, Snow P, Simmons SJ, Tjoa BA, Rogers MK, Brandt J, Healy CG, Bolton WE, Rodbold D: Use of Artificial Neural Network in Evaluating Prognostic Factors Determining the response to dendritic cells pulsed with PSMA peptides in prostate cancer Patients . Prostate. January 2000, 42 (1) :67-72.
51. McNeel DG, Disis ML: Tumor vaccines for the management of prostate cancer. Arch Immunol Ther Exp (Warsz). 2000, 48 (2) :85-93. Review.
52. Heiser A, Dahm P, Yancey DR, Maurice MA, Boczkowski D, Nair SK, Gilboa E, Vieweg J. Human dendritic cells transfected with RNA encoding prostate-specific antigen prostate-specific CTL responses Stimulate in vitro. J Immunol. 2000 May 15, 164 (10) :5508-14.
53. Girls Bauer N, Harris DT, Spitler LE, Whiteside TL. Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer.Prostate. 2000 May 1, 43 (2) :88-100.
54. Pirtskhalaishvili G, Shurin GV, Gambotto A, Esche C, Wahl M, Yurkovetsky ZR, Robbins PD, Shurin MR: Transduction of dendritic cells with Bcl-xL Increases Their Resistance to prostate cancer-induced apoptosis and antitumor effect in mice. J Immunol. 2000 August 15, 165 (4) :1956-64.
55. Tjoa BA, Murphy GP: Development of dendritic-cell based prostate cancer vaccine. Immunol Lett. 2000 September 15, 74 (1) :87-93. Review.
56. Nouri-Shirazi M, Banchereau J, Bell D, Burke Holder S, Kraus ET, Davoust J, Palucka KA: Dendritic cells capture killed tumor cells and present antigens to Elicit Their tumor-specific immune responses. J Immunol. 2000 Oct 1; 165 (7) :3797-803.
57. Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV, Valone FH: Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol. December 1 2000, 18 (23) :3894-903.
58. Pirtskhalaishvili G, Nunez A, Esche C, Shurin GV, Huland E, Huland H, Shurin MR: Human prostate cancer regulates generation and maturation of monocyte-derived dendritic cells. Prostate. 1 January 2001, 46 (1) :68-75.
59. Mincheff M Altankova I Zoubak S, Tchakarov St, Btoev Ch, Petrov St., Krusteva G Kurtev P, Dimitrov V, Ilieva M, Georgiev G, T Lissitchkov, Chernozemski Iv, Meryman HT: In Vivo Transfection and / or cross- priming of dendritic cells following DNA and adenoviral immunizations for immunotheraphy _Changues of cancer in peripheral mononuclear subsets and intracellular IL-4 and IFN-gamma lymphokine profile. Crit Rev Oncol Hematol. 2001 Jul-Aug, 39 (1-2) :125-32.
60. Fong L, Brockstedt D, BENIKE C, Breen JK, Strang G, Ruegg CL, Engleman EC. Dendritic cell based vaccination xenoantigen for prostate cancer immunotherapy. J Immunol. 2001 December 15, 167 (12) :7150-6.
61. Kiessling A, Schmitz M, Stevanovic S, Weigle B, Holig K, Fussel M, Fussel S, Meye A, Wirth MP, Rieber EP. Prostate stem cell antigen: Identification of immunogenic peptides and assessment of reactive CD8 + T cells in prostate cancer patient. Int J Cancer. 2002 December 1, 102 (4) :390-7.
62. Engleman EG: Dendritic cell based cancer immunotherapy. Semin Oncol. June 2003, 30 (3 Suppl 8) :23-9. Review.
63. Ciavarra RP, Brown RR, Holterman DA, Garrett M, Glass WF 2nd, Wright GL Jr, Schell Hammer PF, Somers KD. Impact of the tumor micro-environment on Infiltrating host cells and the efficacy of FLT3 ligand combination immunotherapy Evaluated in a mouse model of prostate cancer treatment. Cancer Immunol Immunother. 2003 June 24 [Epub ahead of print].
64. Zhang S, Zeng G, Wilkes DS, Reed GE, McGarry RC, Eble JN, Cheng L. Dendritic cells transfected with interleukin-12 and pulsed with tumor extract inhibit growth of murine prostatic carcinoma in vivo. Prostate. 2003 June 1, 55 (4) :292-8.
65. Kiessling A, Fussel S, Schmitz M, Stevanovic S, Meye A, Weigle B, Klenk U, Wirth MP, Rieber EP. Identification of an HLA-A * 0201-restricted epitope derived from T-cell prostate cancer-associated protein the trp-p8. Prostate. 2003 September 1, 56 (4) :270-9.
66. Chakraborty NG, Stevens RL, Mehrotra S, Laska E, Taxel P, Sporn JR, Schauer P, Albertsen PC. Recognition of PSA-derived peptide antigens by T cells from prostate cancer without any prior stimulation Patients. Cancer Immunol Immunother. August 2003, 52 (8) :497-505. Epub 2003 June 03.
67. Wolchok JD, Gregor PD, Nordquist LT, Slovin SF, Scher HI: DNA vaccines: an active immunization strategy for prostate cancer. Semin Oncol. 2003 Oct; 30 (5) :659-66. Review.
